Search Result

Results for "

thromboxane synthesis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	COX (7) Isotope-Labeled Compounds (1) Lipoxygenase (1) NF-κB (1) p38 MAPK (1) PDGFR (2) PGE synthase (2) Phosphodiesterase (PDE) (2) Platelet-activating Factor Receptor (PAFR) (1) Prostaglandin Receptor (7) Reference Standards (2) Thrombin (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (17) Inflammation/Immunology (2) Neurological Disease (2)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: DNA/RNA Synthesis

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18763

Indobufen 2 Publications Verification Ibustrin	COX	Cardiovascular Disease
Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A₂ (TxA₂) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .

HY-B1016

Trapidil AR-12008	PDGFR Phosphodiesterase (PDE) Prostaglandin Receptor	Cardiovascular Disease Neurological Disease
Trapidil (AR-12008) is an orally active vasodilator and antiplatelet agent. Trapidil antagonizes platelet-derived growth factor (PDGF), inhibits phosphodiesterase, thromboxane A₂ synthesis and pro-inflammatory cytokine production. Trapidil promotes prostacyclin biosynthesis, reduces lipid peroxidation, regulates nitric oxide metabolism, and inhibits cell proliferation and migration. Trapidil exerts tissue-protective effects, regulates bone turnover, and inhibits pyroptosis via the GPX3/Nrf2 pathway. Trapidil is applicable to research related to renal ischemia-reperfusion injury, chronic stable angina, restenosis, meningioma, diabetic cardiomyopathy and peripheral nerve crush injury .

HY-141469

6,9,12,15,18-Heneicosapentaenoic acid HPA; Heneicosapentaenoic acid methyl ester	PGE synthase Lipoxygenase	Cardiovascular Disease Neurological Disease
6,9,12,15,18-Heneicosapentaenoic acid (HPA) is a ∆5 desaturase inhibitor. 6,9,12,15,18-Heneicosapentaenoic acid serves as a weak substrate for Prostaglandin H synthase and 5-lipoxygenase, yet it inactivates Prostaglandin H synthase at a rate comparable to that of AA, EPA and DHA. 6,9,12,15,18-Heneicosapentaenoic acid is a weak inducer of Aacyl-CoA oxidase. 6,9,12,15,18-Heneicosapentaenoic acid incorporates into phospholipids and triacylglycerols in cell culture. 6,9,12,15,18-Heneicosapentaenoic acid can be used in research related to liver cancer .

HY-120442

(±)16(17)-DiHDPA	COX	Cardiovascular Disease
(±)16(17)-DiHDPA is a epoxygenase metabolite of docosahexaenoic acid (HY-B2167). (±)16(17)-DiHDPA inhibits platelet aggregation at concentrations below those affecting thromboxane synthesis .

HY-120178

(±)7(8)-DiHDPA	COX	Cardiovascular Disease
(±)7(8)-DiHDPA is a epoxygenase metabolite of docosahexaenoic acid (HY-B2167). (±)7(8)-DiHDPA inhibits platelet aggregation at concentrations below those affecting thromboxane synthesis .

HY-129496

NP-313	Thrombin	Cardiovascular Disease
NP-313 is a potent antithrombotic agent that inhibits platelet aggregation and activation. NP-313 has dual inhibition of thromboxane A 2 synthesis and selective inhibition of SOCC-mediated Ca ²⁺ inward flow .

HY-114564

Satigrel E5510	Prostaglandin Receptor	Cardiovascular Disease
Satigrel (E5510) is a potent inhibitor of platelet aggregation. Satigrel inhibits collagen- and arachidonic acid-induced platelet aggregation through preventing thromboxane A2 synthesis by selective inhibition of the target enzyme, PGHS1, which exists in platelets. Satigrel inhibits PGHS1 (IC₅₀: 0.081 μM) and PGHS2 (IC₅₀: 5.9 μM). Satigrel is against Type III PDE, Type V and Type II (IC₅₀: 15.7 μM, 39.8 μM and 62.4 μM, respectively) .

HY-14654B

Aspirin DL-lysine Acetylsalicylic acid DL-lysine; ASA DL-lysine	COX NF-κB p38 MAPK	Cardiovascular Disease Others Inflammation/Immunology
Aspirin DL-lysine (ASA DL-lysine) is a lysine-containing aspirin derivative. Aspirin DL-lysine inhibits cyclooxygenase (COX) in platelets, blocks the synthesis of thromboxane A2 (TXA2), and thus inhibits platelet aggregation and activation. Aspirin DL-lysine can be used to study thrombin generation in patients with unstable angina pectoris .

HY-165587

BM-573	Prostaglandin Receptor	Cardiovascular Disease
BM-573 is an orally active dual thromboxane A₂ (TXA₂) modulator with an IC₅₀ of 1.3 nM. BM-573 possesses both thromboxane synthase (TxAS) inhibition and thromboxane receptor (TP) antagonistic effects. BM-573 can completely inhibit platelet aggregation induced by Arachidonic acid (HY-109590) or U-46619 (TXA₂ analogues). BM-573 completely blocks the generation of TXB₂ (the stable metabolite of TXA₂) in human platelets and does not inhibit cyclooxygenase (COX-1/COX-2), thus avoiding interference with other prostaglandin synthesis. BM-573 has an inhibitory effect on U-46619-induced contractions in rat gastric fundus smooth muscle (ED₅₀ = 4.2 μM), but has no effect on contractions caused by PGE₂, PGF₂α, or PGI₂. BM-573 can be used in the study of atherosclerosis, myocardial infarction, pulmonary hypertension and shock .

HY-B1016R

Trapidil (Standard) AR-12008 (Standard)	Reference Standards PDGFR Phosphodiesterase (PDE) Prostaglandin Receptor	Cardiovascular Disease Cancer
Trapidil (Standard) (AR-12008 (Standard)) is the analytical standard of Trapidil (HY-B1016R). This product is intended for research and analytical applications. Trapidil (AR-12008) is an orally active vasodilator and antiplatelet agent. Trapidil antagonizes platelet-derived growth factor (PDGF), inhibits phosphodiesterase, thromboxane A2 synthesis and pro-inflammatory cytokine production. Trapidil promotes prostacyclin biosynthesis, reduces lipid peroxidation, regulates nitric oxide metabolism, and inhibits cell proliferation and migration. Trapidil exerts tissue-protective effects, regulates bone turnover, and inhibits pyroptosis via the GPX3/Nrf2 pathway. Trapidil is applicable to research related to renal ischemia-reperfusion injury, chronic stable angina, restenosis, meningioma, diabetic cardiomyopathy and peripheral nerve crush injury.

HY-106066

Dazmegrel UK38485	Prostaglandin Receptor	Cardiovascular Disease
Dazmegrel (UK-38485) is a thromboxane synthetase inhibitor which inhibits Thromboxane A2 (TXA2) synthesis and exhibits antiplatelet vasodilator effects. Dazmegrel can be utilized in thrombosis research .

HY-19039

Y-20811 sodium	Prostaglandin Receptor	Cardiovascular Disease
Y-20811 sodium is a selective and orally active thromboxane synthetase inhibitor. Y-20811 sodium can irreversibly inhibit thromboxane (TX) A2 synthesis. Y-20811 sodium can be used for the research of cardiovascular disease, such as thrombosis .

HY-19084

Ro-24-0238	Platelet-activating Factor Receptor (PAFR)	Inflammation/Immunology
Ro-24-0238 is an antagonist of platelet activating factor (PAF) and inhibitor of **thromboxane synthesis**, used for lessening the inflammation and damage resulting from a local release of PAF.

HY-18763A

Indobufen sodium Ibustrin sodium	COX	Cardiovascular Disease
Indobufen sodium is a platelet aggregation inhibitor. Indobufen sodium is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen sodium suppresses thromboxane A₂ (TxA₂) synthesis. Indobufen sodium down-regulates tissue factor (TF) in monocytes .

HY-129199

U-51605	PGE synthase	Cardiovascular Disease
U-51605 is a platelet aggregation inhibitor and inhibits thromboxane synthesis. U-51605 is also a prostaglandin I2 synthase inhibitor and can inhibit the retinal vasodilation response induced by NO donors (such as NOR3) .

HY-18763S

Indobufen-d5 Ibustrin-d₅	Isotope-Labeled Compounds COX	Cardiovascular Disease
Indobufen-d₅ is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .

HY-18763R

Indobufen (Standard) Ibustrin (Standard)	Reference Standards COX	Cardiovascular Disease
Indobufen (Standard) is the analytical standard of Indobufen. This product is intended for research and analytical applications. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A₂ (TxA₂) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .

HY-123400

Samixogrel DTTX30; DT-TX 30 SE	Prostaglandin Receptor	Cardiovascular Disease
Samixogrel is an inhibitor of thromboxane A2 receptor and **thromboxane synthesis** .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-141469

6,9,12,15,18-Heneicosapentaenoic acid HPA; Heneicosapentaenoic acid methyl ester	Structural Classification Animals Lipid Source Classification	PGE synthase Lipoxygenase
6,9,12,15,18-Heneicosapentaenoic acid (HPA) is a ∆5 desaturase inhibitor. 6,9,12,15,18-Heneicosapentaenoic acid serves as a weak substrate for Prostaglandin H synthase and 5-lipoxygenase, yet it inactivates Prostaglandin H synthase at a rate comparable to that of AA, EPA and DHA. 6,9,12,15,18-Heneicosapentaenoic acid is a weak inducer of Aacyl-CoA oxidase. 6,9,12,15,18-Heneicosapentaenoic acid incorporates into phospholipids and triacylglycerols in cell culture. 6,9,12,15,18-Heneicosapentaenoic acid can be used in research related to liver cancer .

HY-120178

(±)7(8)-DiHDPA	Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	COX
(±)7(8)-DiHDPA is a epoxygenase metabolite of docosahexaenoic acid (HY-B2167). (±)7(8)-DiHDPA inhibits platelet aggregation at concentrations below those affecting thromboxane synthesis .

Cat. No.	Product Name	Chemical Structure

HY-18763S

Indobufen-d5
Indobufen-d₅ is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.

thromboxane synthesis

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products